Pulmonary Deposition of Ultrasound Rock Salt Aerosol Inhalation Therapy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJingen Xia

About this trial

In the in vitro modeling phase, the investigators plan to use a realistic human upper respiratory tract model and an asymmetric ideal bronchial tree model. By combining 3D printing experiments with CFD simulations, the investigators will investigate the respiratory tract deposition rate and distribution of micro - moist particles in ultrasound rock salt aerosol inhalation therapy. This will be compared with a small - volume nebulizer to verify the effectiveness of ultrasound rock salt aerosol inhalation therapy and lay the foundation for further research on the application of this inhalation technique to other drug formulations.

In the clinical phase, the investigators plan to have subjects inhale radioactive aerosols and use PET/CT imaging technology to assess the deposition rate of aerosol particles in the lungs. By quantitatively analyzing the images, the investigators will study their distribution characteristics in real human bodies to verify the accuracy of the in vitro models and the potential for clinical application.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Crossover

Treatments tested in this trial

  • USN before SVN

    Device

    The group that received ultrasonic rock salt aerosol inhalation therapy followed by small-volume nebulized inhalation therapy.

  • SVN before USN

    Device

    The group that received small-volume nebulized inhalation therapy followed by ultrasonic rock salt aerosol inhalation therapy.

Treatment groups

26 Participants
are divided into 2 treatment groups
Group A: USN before SVNExperimental treatment 1 intervention
Group B: SVN before USNExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

In Vitro Model Pulmonary Deposition Rate

Aerosol lung deposition rate calculated by in vitro model

Time frame
Immediately after nebulization
2

Pulmonary Drug Deposition Rate

Defined as the percentage of drug deposition in the lungs, relative to the whole inhalation volume

Time frame
Immediately after nebulization

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jingen Xia

Lead sponsor

China-Japan Friendship Hospital

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: